Mowla K, Rajai E, Sabbaghan A, Bijan-Zadeh M, Asl J. M. Investigating the Association of PTPN22 Gene Polymorphism R620W with Scleroderma in Southwestern Iran in Khuzestan. Biomed Pharmacol J 2015;8(2)

---

Manuscript received on :
Manuscript accepted on :
Published online on: --

---

How to Citeclose    |   Publication History close

 Views: (Visited 253 times, 1 visits today)    PDF Downloads: 897

Karim Mowla, Elham Rajai, Amin Sabbaghan*, Mehdi Bijan-Zadeh and Javad Mohammadi Asl

Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

DOI : https://dx.doi.org/10.13005/bpj/868

Abstract

Systemic sclerosis is a chronic systemic disease with unknown variety of etiology, and has clinical chronic protests often progressive. Gene PTPN22 R620W polymorphism has been identified as a risk factor in the scleroderma disease, especially the limited one. The aim of this project is studying the relationship between gene PTPN22 R620W polymorphism with scleroderma disease. This was a clinical trial conducted on 70 patients with scleroderma referred to Golestan Hospital, Ahvaz, Iran and 70 healthy subjects with no history of genetic disorders, particularly autoimmune diseases referred to Iran Blood Transfusion Organization as control group. Diagnosis is based on physical examination and confirmation of rheumatologist. Sampling is done through Non-probability sampling convenient sampling. The PTPN22 R620W polymorphism had no significant relationship in all scleroderma patients and control group (P-value: 0.76, OR: 0.61). In addition, the gene in patients with limited scleroderma, diffuse scleroderma patients, scleroderma +ACA, -ACA scleroderma patients was not significantly more than the control group. This study showed that the prevalence of the gene PTPN22 R620W polymorphism in patients with scleroderma and its subtypes is not more than the control group.

Keywords

Systemic sclerosis; ACA; Gene PTPN22; polymorphism R620W